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Abstract 
Human papilloma virus (HPV) has been shown to be a necessary cause for the 
development of cervical cancer.  Cervical cancer is a progressive disease, going 
through pathologically distinct stages ranging from normal cytology to malignancy. 
Precancerous lesions (low and high grade squamous epithelial lesions (SIL)) are 
detectable and treatable.    In addition, women who are infected with human 
immunodeficiency virus (HIV) have been shown to be more likely to be infected with 
HPV than their HIV negative counterparts.  Cervical cancer precancerous lesions 
have also been shown to be more commonly detected in HIV positive than in HIV 
negative women.  Cervical cancer is classified as an acquired immunodeficiency 
syndrome (AIDS)-defining illness. 
The advent of antiretroviral therapy (ART) has seen an increase in the life span of 
HIV positive women.  The use of ART has also seen a decline in the incidence of 
other AIDS-defining illnesses, such as Kaposi sarcoma and non-Hodgkin’s 
lymphoma.  Thus, a reduction in the incidence of cervical cancer among HIV 
positive women using ART is expected.  However, the research thus far has been 
controversial, with some studies showing an increase in the incidence of cervical 
cancer in HIV positive women, others showing a decrease and still others showing 
no difference in the incidence.  The aim of this project was to determine the 
incidence of precancerous lesions in HIV positive women receiving ART and to 
compare this to HIV positive women who are not receiving ART.  
Four hundred HIV positive women were enrolled into the MACH (Management of 
abnormal cytology in HIV-positive women) study from two primary health care clinics 
and one colposcopy clinic, in Cape Town, South Africa.  Enrolment into the study 
was dependent on cervical screening naivety.  At the time of enrolment, ART was 
not available to these women.  However, as ART was rolled out in South Africa, 
women meeting ART eligibility criteria (at the time, CD4 count ≤ 200 cells/ml) were 
started on ART.  Women were followed up at 6 monthly intervals, at which point 
cervical smears were taken and appropriate referral for colposcopy was done. 
Composite diagnoses were generated using both the visual colposcopy result and 
the histology result, where available.  Women were dichotomized into ART and non-
ART groups.  Survival analysis was used to determine the time taken from normal 
cytology to incident SIL.  Entrance into the survival analysis was dependent on a 
baseline cytological/histological diagnosis of normal.  Thus 177 out of the 400 
women were included.  Follow up was censored at the first of SIL detection and 
treatment for SIL.  A Cox model was built to determine the hazard for SIL 
development.  This hazard was adjusted for ART status, CD4 count and age.  CD4 
count was treated as a time varying covariate. 
Women older than 40 years had a showed a 58% reduction in the progression of 
cervical disease from normal to SIL compared to women younger than 40 years. 
Women with baseline CD4 counts > 500 cells/ml had a 67% decrease in SIL 
development compared to those with a baseline CD4 count ≤ 200 cells/ml. 
Similarly, those with CD4 counts between 201 and 500 cells/ml showed a 35% 
reduction in cervical disease progression. 
ii 
The unadjusted incidence rate of SIL in women not receiving ART was 28.5 per 100 
person years and in women who had initiated ART it was 30.82 per 100 person 
years. There was therefore no difference in the incidence rate of SIL between the 2 
groups (RR=1.08; 95% CI 0.64-1.75). 
The unadjusted hazard ratio for progression to SIL was 1.3 (0.5-3.2) for those 
receiving ART compared to those not receiving ART.  Adjusting for CD4 count and 
age, the hazard ratio was 0.9 (0.4-2.5).  The adjusted hazard ratio for SIL 
development with a CD4 count > 200 cells/ml was 0.5 (0.2-0.9) compared to a CD4 
count ≤ 200 cells/ml.  The adjusted hazard ratios for age 30-39 years and ≥ 40 years 
were 0.9 (0.6-1.5) and 0.4 (0.2-0.9) respectively, compared to age < 30 years. 
ART has been scaled up and since the start of its roll out, the eligibility criteria has 
changed from CD4 count ≤ 200 cells/ml to CD4 count ≤ 350 cells/ml.  The longevity 
of HIV positive women can approach that of HIV negative women if ART initiation is 
started early enough.  In light of this and of the fact that cervical lesions are more 
frequently detected in HIV positive women, cervical screening and referral services 
should be strengthened. 
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Protocol Summary  
 
Invasive cervical cancer is considered an acquired immune deficiency syndrome 
(AIDS)-defining illness.1  The odds of invasive cervical cancer (ICC) in human 
immunodeficiency virus (HIV)-positive women has been shown to be 6.5 times that 
in HIV negative women, while the odds of cervical intraepithelial neoplasia (CIN) 2 
and 3 in HIV positive women is 10.4 times that seen in HIV negative women.2  Of 
women aged 15-49 years old, 18.5 % are HIV positive.3  This represents a 
significant number of women at increased risk for development of cervical lesions 
and ICC.  The advent of antiretroviral therapy (ART) has resulted in a decrease in 
the incidence of other AIDS-defining illnesses; however the impact of ART on the 
incidence of ICC in HIV positive women remains controversial.  In this study 400 HIV 
positive women have been enrolled and cervical cytology and/or histology 
diagnoses were obtained at 6 monthly intervals.  The rate of cervical disease 
progression will be determined using survival analysis and the rates between those 
who initiate ART use and those who do not will be compared and a rate ratio will be 
calculated.  Other explanatory variables to be analysed include age, baseline CD4 
count, baseline viral load and baseline human papilloma virus (HPV) status.  
Women were deemed HPV positive if they tested positive for high risk HPV strains 
and HPV negative if they tested negative for high risk HPV strains.  In addition, Cox 
proportional hazards ratios will be determined for the risk of SIL.  Crude and 
adjusted hazard ratios will be generated for the effect of ART, CD4 count and age 
on SIL incidence.   
Introduction 
Background 
South Africa has an estimated human immunodeficiency virus (HIV) prevalence of 
10.2%, one of the highest in the world and has the largest HIV epidemic in the 
world, with an estimated 5.5 million people infected.3   The prevalence of (HPV) 
among South African women is high, with an estimated 15.5% of women with 
normal cervical cytology being positive for HPV.4  This is higher than the world 
prevalence of 10%. 
Furthermore, it has also been found that women who are HIV positive are more 
likely to be infected with HPV.  A study comparing the prevalence of HPV between 
HIV positive and HIV negative women found that HIV positive women were more 
likely to have high, low and intermediate risk HPV infections (1.8, 2.1 and 2.7 times, 
respectively) than their HIV negative counterparts.5    Similarly, Ng’andwe et al7 
reported a 1.8 fold increase in high risk HPV infections in HIV positive women 
compared to their HIV negative counterparts, in Zambia.  There was also a 2.1 and 
2.7 fold increase in the likelihood of intermediate and low risk HPV infections in HIV 
positive women.  In a Cameroonian cohort, it was found that HIV positive women 
were more likely to have multiple and high risk HPV subtypes compared to their HIV 
negative peers.7 
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In developed countries the incidence of cervical cancer has been reduced due to the 
establishment of good screening systems.  However in the developing world setting 
up adequate screening and diagnostic systems has proved challenging in the face 
of weak infrastructure, resulting in an unnecessarily high incidence of cervical 
cancer.  This poor screening and diagnostic system further compounds the 
phenomenon of a strong association found between HIV positivity and incidence 
and persistence of HPV infection, as well as the higher incidence and prevalence of 
squamous intraepithelial lesions (SIL).8  Furthermore, the increase in access to 
antiretroviral therapy heralds an age in which there is an increase in the lifespan of 
these HIV positive women, further emphasising the importance of the need for 
effective cervical screening and diagnostic systems. 
Six et al9 found that the one-year prevalence in a cohort of HIV negative and 
positive women was over 4 times higher in the HIV positive women than in the HIV 
negative women.  The incidence of SIL was 5.5 times higher in the HIV positive 
women than in their HIV negative counterparts and progression from low grade SIL 
(LSIL) to high grade SIL (HSIL) occurred in 38% of HIV positive women, but not in 
the HIV negative controls at all over the one year follow-up period.  Massad, et al10 
found that over a 5 year follow up period 73% of all HIV positive study participants 
presented with at least 1 cytological abnormality of the cervix compared to 42.3% of 
all HIV negative participants.  HIV status was found to be a predictor of cytological 
abnormalities and the risk ratio of LSIL between HIV positive women and HIV 
negative women was 4. 
The advent of the ART era saw a drop in incidence and mortality due to AIDS-
defining illnesses, such as Kaposi Sarcoma11 and non-Hodgkin’s Lymphoma12 in 
Europe.  However, the same cannot be said for cervical cancer.  Various studies 
have yielded conflicting results regarding the association between ART and cervical 
disease progression, and as a result it is still unclear whether the use of ART results 
in a decrease in cervical neoplasias.  Some of the evidence points to a decrease in 
the occurrence of cervical dysplasia, however other evidence indicates that there is 
no change in prevalence of SIL among HIV positive women on ART. 
Heard et al13 found that the prevalence of SIL among HIV positive women 
decreased significantly after a median period of 5 months after starting ART in 
France.  A cohort study by Minkoff et al14 in USA found that women on ART were 
32% less likely to have progression of cervical disease over 6 months.  In Italy, 
Soncini et al15 found that over a 37 month follow up period, women on highly active 
ART (ART) had a 70% reduction in the risk for developing CIN compared to HIV 
positive women not on ART, over the same time period. 
On the other hand, monitoring of the rate of progression of cervical disease in 163 
HIV positive women in Italy over a mean period of 15.4 months16 showed that there 
was no difference between women on ART and women not on ART.  In addition, 
Schuman et al17 reported that ART-use did not result in a decreased risk of incident 
SIL in US women.  
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Aim 
The aim of this study is to compare the rate of cervical disease progression in HIV 
positive women who are have initiated ART use to that in HIV positive women who 
have not initiated ART use. 
Objectives 
The specific objective is to compare the rate of cervical disease progression 
between women receiving ART and women not receiving ART.  The secondary 
objectives are to stratify the rates of disease progression by baseline CD4 count, 
baseline viral load, baseline HPV status and age; and also to determine the hazard 





This is a secondary analysis of data generated in the Management of Abnormal 
Cytology in HIV-infected women (MACH) cohort study.18  Women were enrolled 
from primary health care clinics or from a colposcopy clinic in Cape Town, South 
Africa. Women were enrolled within a 10 month period between March 2002 and 
January 2003.  Women were followed up for a median of 2.5 years, although 39 of 
the 400 (just under 10%) were followed up for 9 years.  Those women who were not 
followed up to the final visit date (the 18th biannual visit) were either classified as lost 
to follow up or confirmed as dead.  
Study population 
Four hundred women were enrolled into the study from two primary health care 
clinics and one colposcopy clinic, to which they were referred if they had an 
abnormal Pap smear. Women met the inclusion criteria if they were HIV positive and 
previously unscreened for cervical disease.   This included the women who were 
recruited from the colposcopy clinic, who also had to be previously unscreened at 
the clinic that referred them for colposcopy. 
Measurement 
The outcome of interest in this study is SIL.  SIL will include both high grade and low 
grade SIL.  Screening of the cervix uteri was undertaken every 6 months and a 
cervical cytological diagnosis was obtained.  Women were referred for colposcopy if 
the cytological diagnosis indicated this.  If an acetowhite lesion was seen under the 
colposcope, a punch biopsy of this area was obtained.  This sample was used to 
make a histologic diagnosis. 
If both a visual colposcopy and a histological diagnosis are available, a composite 
diagnosis will be constructed and used in analysis.  CIN2 and CIN3 will be classified 
as HSIL regardless of the visual colposcopy result.  CIN1 will be classified as HSIL if 
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the visual colposcopy is HSIL and LSIL if the visual colposcopy is LSIL or normal.  If 
only a cytological diagnosis is available, this will be used in analysis. 
Other variables to be used in the analysis are: 
 CD4 count:  this will be used as a categorical variable. 
 HPV status: this will be used as a categorical variable. 
 Age: this will be used as a categorical variable. 
 Viral load: the log of viral load will be used as a categorical variable. 
 ART status: this will be used a categorical variable. 
Data management and analysis 
The database is maintained by staff in the colposcopy clinic where the participants 
receive their consultations.  The data is stored using Microsoft Access.  The data will 
be transferred from Access to Stata, which will be used for all data management 
including data cleaning, manipulation and analysis. 
The data will be analysed using survival analysis.  The event of interest will be 
squamous cell intraepithelial lesions and thus I will be evaluating the time from entry 
into the study until the first time this event is experienced.  Follow up will be 
censored at the first of SIL diagnosis and receiving treatment for cervical disease.   
Kaplan Meier survival plots will be generated, and the principle outcome to be 
evaluated is the effect of ART on the time to SIL.  Therefore, survival will be 
stratified by ART status.  The analysis will also be stratified by baseline CD4 count, 
baseline viral load, baseline HPV status and age.   
A Cox proportional hazards model will be built in order to determine the hazard 
ratios for SIL for each covariate.  This type of model is appropriate for dealing with 
loss to follow up, a phenomenon to which longitudinal cohort studies are more often 
than not subject to.  In addition it also does not make any underlying assumption 
about the baseline hazard of individual participants and assumes that the hazards 
remain proportional and constant over time. 
Ethics 
Human ethics approval for this study was obtained from the University of Cape 
Town Health Science Human Research Ethics Committee.  The data was routinely 
collected each time a participant visited the clinic.  Therefore analysis of this data 
will not result in any foreseeable harm to the participants.  Personal identifiers such 
as names and South African identity numbers have been removed from the dataset, 
so therefore confidentiality of participants is ensured.   
The results of this study will be disseminated by submission of abstracts to relevant 
conferences for presentation, as well as submission of abstracts to peer reviewed 
journals for publication.  This should ensure adequate dissemination of the study 
results at both the national and international level.  
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Study limitations 
The validity of the study is dependent on the accurate entry of data.  As far as 
possible, data entries will be scrutinized and the plausibility considered.  For 
example, dates will be checked for errors such as dates occurring in the future or 
occurring in the past (in the case of participant consultation dates). 
Self-report biases could affect the baseline demographic comparisons between 
different groups.  For example, questions requiring recall on the part of the 
participant could be incorrectly answered, resulting in inflated or deflated differences 
between comparison groups. 
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Introduction 
Cervical cancer is the second commonest cancer among South African women.1  
Cervical disease is the progressive alteration of the cytology of the cervix from that 
of normal cytology to cervical cancer.  There are many risk factors for cervical 
cancer, including smoking,2 Clamydia trachomatis infection,3 long term use of oral 
contraceptives,4 and early age at sexual debut, increased number of sexual partners 
over a lifetime and sexual partners with high risk contacts.5  However, a necessary 
cause for cervical disease is infection with human papilloma virus (HPV).6  The 
disease takes many years to progress and goes through multiple intermediate 
stages.   Following infection, the cervical cytology will change from normal to low 
grade squamous intraepithelial lesions (LSIL).  It is notable that at this stage the 
cytology may spontaneously regress to a normal cytological state.7  However, 
further progression can occur in which the cervical lesions develop into high grade 
squamous intraepithelial lesions (HSIL).  Further progression from HSIL will result in 
a malignant cervix, or cervical cancer. 
Multiple HPV types exist.  Different subtypes are responsible for different types of 
pathological manifestations in different tissue types.  HPV-16 and HPV-18 are most 
commonly associated with a high risk for cervical cancer.8  In addition, HPV 16 is 
also associated with anal intraepithelial neoplasia and anal cancer as well as 
cancers of the head and neck.9, 10  Others, such as HPV-6 and HPV-11 are more 
closely associated with genital warts. 11, 12  Thus it is only infection in the cervix with 
high risk types for cervical lesions which is of concern for cervical cancer.   
Two different vaccines exist which elicit immune responses to these high-risk HPV 
types.  These are Gardasil13 and Cervarix14.  Gardasil is quadrivalent and targets 
HPV 16 and 18 as well as the strains associated with genital warts, while Cervarix is 
a bivalent vaccine and only targets HPV 16 and 18.  Administration of these 
vaccines is aimed at females who are not yet sexually active or who have only 
recently become sexually active15.  It is a form of primary prevention.  However, 
these vaccines are expensive and usually not available through a public health care 
system.  In South Africa, the vaccine is currently being administered to girl learners 
aged 9 and in grade 4.  This is being implemented in the form of a mass vaccination 
campaign and will take place every year from 2014 to 2016.  Thereafter the process 
will be reviewed and evaluated, in order for consideration for inclusion of the vaccine 
into the Expanded Programme on Immunisation.16 
In the absence of primary prevention, secondary prevention in the form of a 
screening system is the principle way in which precancerous lesions are identified.  
During screening, a cervical smear, also known as a Papanicoloau smear, is 
collected.  The smear is stained and examined under a microscope for identification 
of cervical lesions.  High grade lesions or worse are eligible for a diagnosis by 
colposcopy, in which the cervix is examined using a colposcope.  If required, a 
biopsy may be taken and sent for histological analysis, or the diagnosis may be 
made visually.  For HSIL, procedures such as long loop excision of the 
transformation zone (LLETZ) or cryotherapy will be performed to remove the 
pathological tissue and thus preventing progression to cervical cancer.17 
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The South African guidelines on cervical smears and colposcopy18 state that women 
aged 30 years and older should have a cervical smear done once every 10 years 
(i.e. 3 per lifetime).  The guidelines for follow up of different smear outcomes are as 
follows: 
 Normal: return for a cervical smear in 10 years. 
 LSIL: return for a cervical smear after 1 year.  If after a year the result is 
normal, follow up is per protocol.  If the result is another LSIL, the woman is 
to be referred for colposcopy. 
 HSIL or worse: the woman is to be referred for colposcopy. 
In South Africa, the processes of screening and diagnosis occur at two different 
levels of health care delivery, namely primary and tertiary levels respectively.  
Women attend the primary health care facilities for a cervical smear to be taken.  
The smear is sent to a laboratory for analysis and based on the outcome, the 
woman may or may not be referred to a colposcopy clinic.  Often times, the poor 
follow up of patients at the primary level results in many women who require 
colposcopy failing to attend the colposcopy appointment at tertiary level.   Regarding 
cervical and colposcopy services, poor follow up refers to poor recording of patient 
information such as address and telephone numbers, failure to action the recall of 
patients who require further treatment, etc.  Figure 1 shows the link between primary 
and tertiary cervical services and cervical smear outcomes and tertiary treatment. 
 
 
Figure 1: Figure illustrating different service levels for screening and diagnosis of 
cervical disease. 
The World Health Organisation has guidelines for screening and treatment policies 
which allow decision makers to choose appropriate policies based on contextual 
factors19.  In areas where there is poor follow up of patients, poor training of health 
care workers and low coverage of women they recommend that a screen-and-treat 
approach be used.   In a randomised controlled trail conducted by Denny et al20 it 
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was found that women who tested positive on either a HPV test (which detects HPV 
DNA) or visual inspection with acetic acid (VIA) (which allows lesions to be visible to 
the naked eye at the point of care) and were treated immediately with cryotherapy 
had a 77% and 37% reduction in the detection of high grade lesions at 12 months 
follow up, respectively, compared to women who received delayed evaluation of 
lesions. 
Natural history of HPV 
Papilloma viruses are double-stranded DNA viruses belonging to the family 
Papillomaviridae.21  There are 29 genera made up of 180 papillomavirus types, of 
which 120 are human papilloma viruses.  They are species-specific and therefore 
human papilloma viruses infect only humans.  Among the different HPVs, tissue-
specific tropism is displayed.  Thus there are particular HPV types that infect the 
different tissues of the cervix, vagina, vulva, etc.  Specific HPV types also infect the 
head and neck.  Furthermore, HPV types can be considered to be either low- or 
high-risk, and it is this which determines whether or not infection in squamous 
epithelial tissue has the potential to develop into cancer.  For example, HPV types 6 
and 11 infect the genital tract but are low-risk types and therefore cause benign 
genital warts, while HPV types 16 and 18 infect the genital tract but are high-risk 
types and cause cervical cancer, which is a life-threatening illness.   
All HPV’s DNA contain 3 regions.22  These are an upstream regulatory region, which 
contains genetic sequences involved in control of viral transcription and translation; 
an early region containing open reading frames which determine the carcinogenic 
properties of the virus; and a late region which contains open reading frames coding 
for viral structural proteins.  The early genes E6 and E7, which are present in HPV 
16 and 18 genomes, have been shown to bind the mammalian proteins p5323 and 
pRb24, both tumour suppressing proteins.25, 26  Binding of these proteins sets the cell 
on a pathological course which ultimately results in cancer. 
HPV employs a number of immune evasion mechanisms.  One of these is molecular 
mimicry.27  The E7 protein has been found to have homologous sequences to 
mammalian proteins such that antibodies produced against E7 may also target XP-
G complementing protein, which is involved in repair of UV-damaged DNA.28  It also 
has regions analogous to RBBP-1, which is involved in cell cycle regulation.29  Thus, 
anti-E7 antibodies may also result in a dysregulated cell cycle. 
Following infection with HPV, expression of MCP-1 is suppressed.30  MCP-1 is a 
chemokine which attracts monocytes and macrophages, so that they are able to 
perform immune surveillance functions.31  Thus by supressing MCP-1 expression, 
cells infected with HPV remain undetected by the immune system. 
The oncoproteins E6 and E7 have also been shown to inhibit IL-8 promoter activity 
and thus IL-8 transcription.32  IL-8 is a pro-inflammatory cytokine and attracts 
neutrophils and granulocytes to the site of infection.33 
Thus, by using these immune evasion mechanisms, HPV may be in a cellular 
environment that is not reactive to the presence of virus.  This is favourable for the 
 Page 4 
 
eventual expression of viral proteins.  Specifically, once the oncoproteins E6 and E7 
are expressed, the cell is set on a pathological pathway.34 
It is unknown why some cervixes will progress to cancer and others do not.  Animal 
models have shed light on the differences in immune responses to HPV infection in 
lesions that are regressing and lesions that are progressing: regressing lesions have 
CD4+ and CD8+ cytotoxic lymphocytes present as well as macrophages.35  The 
environment is also characterised by the presence of pro-inflammatory cytokines as 
well as adhesion markers responsible for trafficking of lymphocytes.  In contrast, 
lesions that are progressing have only CD8+ cytotoxic lymphocytes and 
mononuclear cells 
HPV prevalence 
Worldwide, cervical cancer is the fourth commonest cancer among all women and 
the second commonest among women aged 15-44 years.36  It is estimated that 
roughly half of all women who develop cervical cancer will die from it.  Of women 
with normal cervical cytology, 13.5% are positive for HPV.36 
Infection with HPV occurs soon after sexual debut.37 The majority of these infections 
are cleared spontaneously and the prevalence of HPV decreases with age, until the 
age of 40 and older where an increase in the prevalence among this age group is 
seen.38 The factors associated with the increase in HPV prevalence seen in this 
older age group are unclear.  Possible causes are reactivation of latent HPV 
infections or re-infection with HPV with increasing numbers of sexual partners. 
More than half of deaths due to cervical cancer occur in the developing world.36 
Amongst African women, the prevalence of HPV is nearly two times that of the 
global prevalence, at 24.9%.39  Cervical cancer is also the second commonest 
cancer among African women and the age-standardised mortality rate is 17.5 per 
100 000 women per year. 
In South Africa, the prevalence of HPV among women with normal cytology is 21%.1  
This is higher than the global average of 13.5%. 
HPV and HIV Co-infection 
The risk of HIV acquisition has been shown to be increased by the presence of other 
STIs.40  HPV is the commonest sexually transmitted disease41, and similarly, 
infection with HPV has been shown to increase the risk of infection with HIV.  A 
meta-analysis of studies in which HIV infection following HPV infection were 
analysed showed that the risk of HIV infection while being positive for any type of 
HPV was 1.96 (CI 1.55; 2.49).  For high risk HPV types, the risk of HIV infection was 
1.92 (CI 1.49; 2.46).42 
In addition, cross-sectional studies have shown that HIV positive women are more 
likely to be infected with HPV43, more likely to have persistent HPV infection44 as 
well as more likely to be infected with multiple HPV types.45  HIV positive women are 
also more likely to have cervical cancer presursors.46  Thus the guidelines for 
cervical screening in HIV positive women is slightly different to that of HIV negative 
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women.  In South Africa, it is recommended that HIV positive women be screened 
for cervical cancer precursors once every three years.  The Clinical Guidelines for 
the Management of HIV and AIDS in Adults and Adolescents47 released in 2010 
advise that HIV positive women should be screened every 3 years.  The guidelines 
for referral follow those for HIV negative women, except that a diagnosis of normal 
cytology signals a repeat smear in 3 years’ time and not 10 years. 
Cervical cancer is classified as an AIDS-defining clinical condition.48  That is to say 
that if a HIV positive woman is diagnosed with invasive cervical cancer, she would 
be eligible for antiretroviral therapy regardless of her CD4 count.  It is the only HPV-
related cancer that is considered to be AIDS defining, however other HPV-
associated cancers have been found to occur with increasing frequency among HIV 
positive individuals compared to HIV negative individuals.49  The use of antiretroviral 
therapy has been shown to decrease the risk of developing many other AIDS-
defining conditions, such as Kaposi Sarcoma and non-Hodgkin lymphoma.50, 51, 52  
However, the literature regarding the effect of ARVs on cervical disease progression 
in HIV positive women has been controversial thus far.  While some studies have 
shown a decreased risk for cervical disease progression, others have found no 
difference in the risk between HIV positive and HIV negative women, while others 
have found an increased risk. 
Clearance of high risk HPV subtypes in women with normal cytology has been 
shown to be achieved in 43% and 65% of women followed up for 6 and 18 months, 
respectively.53  HPV negativity in itself is a not a state which can be defined with 
certainty as HPV may be present at levels below the limits of detection of the test.  
Nevertheless, clearing an HPV infection requires cell mediated immunity.54  In HIV 
positive women, immunity levels are lowered and this may explain why HIV positive 
women are more likely to be HPV positive than HIV negative women. 
HPV vaccine  
Two types of vaccines against HPV high risk subtypes have been produced 
(Cervarix and Guardasil13,14).  Cervarix is a bivalent vaccine and has been shown to 
be highly efficacious against both incident and persistent infection with high risk 
HPV types 16 and 18, thus providing protection against cervical lesions.55  Gardasil, 
a quadrivalent vaccine, induces immunity against infection with HPV types 6, 11, 16 
and 18.56  In addition, Gardasil has been shown to provide cross protection against 
HPV types not included in the vaccine.57   
Introduction of either the quadrivalent or the bivalent vaccine into the immunisation 
programme of a country has been shown to result in a decrease in the prevalence of 
high risk HPV types as well as precancerous lesions associated with these 
oncogenic types.58, 59  Furthermore, a trial in which HIV positive women have 
received the vaccine have shown that there is a good immunogenic response in this 
immunocompromised subgroup of women.60  In addition, an immunogenic response 
to HPV vaccine has been shown in both HIV positive women on ART and those not 
on ART.61   
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The safety and immunogenicity of quadrivalent HPV vaccine has also been 
established in HIV positive girls between the ages of 7 and 12.62  This is a promising 
finding as HPV vaccine has been found not to have an effect on clearance of 
existing HPV infections (and HIV positive women are more likely to be infected with 
HPV).63  Thus HIV positive girls can be vaccinated along with their HIV negative 
counterparts, thus preventing possible infection with the relevant types once they 
become sexually active. 
Effect of treatment of high grade lesions 
Women with high grade lesions who receive treatment, where these lesions are 
removed, are at low risk for recurrence of these lesions.  Factors associated with 
recurrence of these lesions are high risk HPV-positivity, lesion grade (cervical 
intraepithelial 2 vs 3), and margin status transformation zone type at removal of the 
lesion.64 Similarly, a low risk for recurrence of high grade lesions after treatment has 
been found in HIV positive women.65, 66  
Effect of ART on cervical disease in HIV positive women 
Progression of the cervical cytology from normal to pathological is a process 
facilitated by the insertion of the HPV genome into the cellular genome and 
expression of the HPV genes by the cellular machinery.  Oncogenic proteins 
encoded by the HPV genome cause the normal cellular process to be arrested and 
instead the cell is set on a pathogenic pathway which results in the development of 
a cancerous cell.67  
This pathway that leads to a cell becoming cancerous is irreversible. Therefore, 
despite the fact that ARVs reverse the immunosuppressive effects of HIV, the 
cancerous pathway itself cannot be reversed.  This may explain why some research 
finds that there is no difference between the incidence of cervical lesions in HIV 
positive women on ARVs and those not on ARVs.  In fact, in this age where ARVs 
are accessible to many HIV positive women, one could argue that the increased 
longevity afforded by these drugs allows for more time for the development of 
cancerous cells of the cervix.  Thus the importance of robust screening and 
diagnostic cervical services for HIV positive women is underscored. 
Several studies have found that the use of ARVs result in decreased incidence of 
cervical lesions.  Kim et al68 found that HIV positive women on ART had a 58% 
reduced risk of SIL development.  They also found a decreased risk for progression 
to SIL with increasing CD4 count.  Similarly, Adler et al69 found that women on ART 
with normal cervical cytology at baseline were 38% less likely to have a cervical 
lesion incident than those not on ART.  Furthermore, they also found that women 
who showed regression of cervical lesions were 2.61 times more likely to be on 
ART. 
A systematic review by Cobucci et al70 found that ARVs increased the risk of 
invasive cervical cancer by 46%.  The review included 5 observational studies 
ranging in time from 2001 to 2010. 
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The different outcomes in HPV clearance, SIL incidence and cervical disease 
progression and regression that are found in different studies are possibly due to the 
different baseline conditions in study participants or in the different study entrance 
criteria.  Paramsothy et al71 found that for women with a baseline cervical cytology of 
normal, ART was not associated with clearance of HPV infection.  They also found 
that in women with LSIL or HSIL, ART was associated with HPV clearance.  In 
addition, despite the association of ART with HPV clearance, in women with cervical 
dysplasia, ART was not associated with regression of these lesions.     
In addition, an analysis of trends in AIDS-defining cancers in the era of ARVs found 
that the risk for incidence of these was still higher than in the HIV-negative 
population.72  Thus in spite of the increasing accessibility of HIV positive women to 
therapy, it remains prudent to provide cervical screening services at a greater 
frequency than that for HIV negative women. 
Conclusion 
The effect of ARVs on the progression of cervical disease in HIV positive women 
has been controversial thus far.  Further studies are warranted to contribute to the 
literature available thus far in order to optimise ARV therapy on HIV positive women, 
who are at higher risk of HPV positivity as well as development of cervical lesions. 
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Background:  Women who are HIV positive have been found to be more likely to be 
infected with Human papillomavirus (HPV) than HIV negative women.  HPV infection 
of the cervix is necessary for the development of cervical cancer, which is an AIDS-
defining illness. The impact of antiretroviral therapy (ART) on the incidence of 
cervical cancer and its precursors is controversial.  We determined the incidence of 
squamous intraepithelial lesions (SIL) in women receiving ART and compared it to 
those women not receiving ART. 
Methods:  400 HIV positive women from a primary healthcare clinic and a 
colposcopy clinic were enrolled.  Women were followed up at 6-monthly intervals at 
which Pap tests and colposcopy were performed, and survival analysis was used to 
determine the time from baseline diagnosis of normal to a diagnosis of SIL. 
Results: Out of 400 women, 177 had a diagnosis of normal at the baseline visit. 
Follow-up was censored at the first of SIL diagnosis and receiving treatment for 
cervical disease.  The incidence rate of SIL in women not on ART was 28.5 per 100 
person years and in women who had initiated ART it was 30.82 per 100 person 
years. There was therefore no difference in the incidence rate of SIL between the 2 
groups (RR=1.08; 95% CI 0.64-1.75). 
Conclusion:  Our results show no difference in the incidence rate of SIL between 
women on ART and women not on ART.  Since ART results in an increased lifespan 
of HIV positive women and since these women are more likely to be HPV positive, 
efforts need to be taken to strengthen cervical screening and referral systems for 
HIV positive women in particular. 
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Introduction 
South Africa has an estimated human immunodeficiency virus (HIV) prevalence of 
10.2%, one of the highest in the world and has the largest HIV epidemic in the 
world, with an estimated 5.5 million people infected.1  The prevalence of human 
papillomavirus (HPV) among South African women is high, with an estimated 
18.4%2 of women with normal cervical cytology being positive for HPV.  The 
prevalence of HPV 16 or 18 among women with normal cytology, high grade lesions 
and cervical cancer is 3.2, 30.3 and 63.9%.2   
Furthermore, it has also been found that women who are HIV positive are more 
likely to be infected with HPV, to have persistent infection with high-risk types of 
HPV, and to be infected with multiple types3, 4, 5  In addition there are data to suggest 
that cervical cancer precursors are more frequently diagnosed in HIV positive 
women and progression to invasive cervical cancer is faster than in HIV negative 
women6, 7. 
Where successful screening programs have been implemented and sustained, as 
has occurred in a number of developed countries8, cervical cancer incidence and 
mortality has been substantially reduced. Few developing countries have had 
sufficient human, financial and health infrastructure resources to either initiate or 
sustain cervical cancer screening programs. The HIV/AIDS epidemic has highlighted 
the need for cervical cancer screening in HIV positive women, particularly women on 
anti-retroviral therapy (ART), who are likely to live longer and therefore are at 
greater risk of developing cervical cancer. 
The advent of the antiretroviral therapy era saw a drop in incidence and mortality 
due to AIDS-defining illnesses, such as Kaposi Sarcoma9 and non-Hodgkin’s 
Lymphoma10.  However, the same cannot be said for cervical cancer.  Various 
studies have yielded conflicting results regarding the association between 
antiretroviral therapy and cervical disease progression, and as a result it is still 
unclear whether the use of antiretroviral therapy results in a decrease in cervical 
neoplasias.  Some of the evidence points to a decrease in the occurrence of cervical 
dysplasia 11,12, however other evidence indicates that there is no change in 
prevalence of SIL among HIV positive women on antiretroviral therapy.13
This study presents the results of a longitudinal study of cervical disease 
progression in a cohort of 400 HIV positive women followed up for 9 years in Cape 
Town, South Africa.  Progression of cervical disease was compared in those women 
who were not on ART and those women who were on ART.  We also report the 
effects of CD4 count on cervical disease as well as the progression of cervical 
disease following treatment for SIL. 
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Methods and Materials 
The methods and materials have been presented previously14.  Briefly, 400 HIV-
positive women were recruited from a primary healthcare clinic and a colposcopy 
clinic between March 2002 and January 2003.  Women had to be previously 
unscreened for cervical cytology and HIV positive to meet inclusion criteria.  Ethics 
approval was obtained from the University of Cape Town’s Research Ethics 
Committee.  Each woman provided written informed consent and underwent the 
following procedures: conventional cytology sampling of the cervix for detection of 
high-risk HPV subtypes and colposcopy with histological sampling if appropriate. 
Cervical smears were analysed by the South African National Health Laboratory 
Service.  For histologic reporting the following nomenclature was used: CIN-1 was 
referred to as LSIL and CIN-2/3 were grouped together and referred to as HSIL.  For 
statistical analysis, both the colposcopic and histologic diagnosis (where available) 
were combined.  This yielded a composite diagnosis which was used as the end 
point in survival analysis. 
Cervical samples were collected using the Qiagen DNA collection device, (Qiagen, 
Gaithersburg, Inc., MD, USA), and assayed for high risk HPV using the Hybrid 
Capture II test (Qiagen, Gaithersburg, Inc., MD, USA).  Details of the assay have 
been described previously14.  Blood was taken at each visit to determine CD4 
counts and HIV viral load.  CD4 counts were determined every 6 months.  HIV viral 
load was determined every 18 months for the first 2 years. 
All acetowhite lesions were biopsied. Women were treated with large loop excision 
of the transformation zone (performed under local anaesthetic in the clinic) if they 
had a histologically confirmed diagnosis of HSIL. 
Women who were eligible for ART initiation (i.e. women with a CD4 count below 200 
cells/mm3 or diagnosed with an AIDS-defining illness) were offered ART through 
primary health care facilities.   
The data were analysed using StataMP 11.0 (StataCorp, College Station, TX).  All 
statistical tests were 2-tailed at α=0.05.  Survival analysis was used to determine 
time from a baseline diagnosis of normal to SIL.  Thus, entry into the statistical study 
required that women be SIL-free at baseline.  Women were censored at the first of 
SIL diagnosis and receiving treatment for cervical disease.  Kaplan-Meier survival 
plots were generated and these were stratified by ART status and CD4 count.  Risk 
ratios for the development of SIL are presented, by ART status, baseline CD4 count, 
baseline HPV status and age.  Cox proportional hazards regression was also 
performed and hazard ratios are presented for SIL development, both crude and 
adjusted for ART status, CD4 count (as a time-varying covariate) and age.
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Results 
Study Sample and Baseline Characteristics 
The baseline sociodemographic characteristics of this cohort have been described 
previously14.  Table 1 shows the baseline characteristics of women who were on 
ART at their final visit and those who were not. 
 Of the 400 women, 114 (28.5%) had died and 172 (43%) were lost to follow up by 
the end of the follow up time.  The final visit date was defined as the 18th biannual 
visit date.  Women who had their last visit date more than 1.5 years before this date 
and who were not confirmed as deceased were considered to be loss to follow up. 
The median CD4 count at baseline for women who had initiated ART by their final 
visit was 217/mm3 compared to 268/mm3 for women who did not start ART.  Overall, 
74% of all women tested positive for high risk HPV at baseline compared to 63% of 
women who did not start ART.   The proportion of women with normal, LSIL and 
HSIL histological diagnoses at baseline were similar amongst those who were on 
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Fifty per cent of the women had initiated ARV treatment by 1281 days or 3.5 years, 










The Kaplan Meier plot in figure 2 shows that there is an increase in the rate of 
progression to SIL with decreasing baseline CD4 count.  Compared to having a 
baseline CD4 count of 200 cells/mm3 or less, the rate ratio of progression to SIL in 
those who had a baseline CD4 count of 201-500 cells/mm3 was 0.65 (95% CI 0.41-
1.04).  For those with a baseline CD4 count greater than 500 cells/mm3 the rate ratio 
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Figure 1: Kaplan Meier plot showing ART initiation over time.   
Figure 2: Kaplan Meier plot showing SIL development over time, stratified by 






baseline CD4 count of 201-500 and greater than 500 cells/mm3 was 35 and 67% 
protective against the development of SIL, respectively. 
Among women who initiated ART, the lowest CD4 counts ranged from 5 to 510 
cells/mm3, with a median CD4 count of 104 cells/mm3.  For women who did not 
initiate ART, the lowest CD4 counts ranged from 4 to 1037 cells/mm3, with a median 
CD4 count of 179 cells/mm3.   Six months prior to starting ART, 59, 34 and 7% of 
women had a diagnosis of normal, LSIL and HSIL, respectively. 
Those who died or were lost to follow up had similar baseline characteristics to 
those who were retained, apart from the median CD4 count and whether or not they 
were on ART at the final visit.  In addition, there was a difference in the median viral 
load between those retained and those who died. 
Table 3: Comparison of baseline characteristics of women who died, were lost to 
follow-up and retained in the cohort. 
Retained 
(n=114) 
Died (n=114) p value* LTFU 
(n=172) 
p value** 





264 130.5 <0.0001 305 0.123 
CD4 200 or less 
(%) 
40 (35.1) 75 (65.8) 43 (25.0) 
CD4 201-500 (%) 58 (50.9) 33 (29.0) 94 (54.7) 
CD4 more than 
500 (%) 
16 (14.0) 6 (5.3) 35 (20.4) 
Median log HIV 
viral load 
(copies/ml) 
4.26 4.81 <0.0001 4.04 0.646 
Prevalence of 
HR-HPV (%) 
76 (66.7) 82 (72.6) 0.334 111 (65.3) 0.811 
Ever smoked 
(n=399) (%) 
12 (10.5) 13 (11.4) 0.832 22 (12.9) 0.551 
Mean age of first 
intercourse 
(range) 
17 (13-23) 16.8 (11-26) 0.468 16.9 (9-
25) 
0.753 
Number of sexual 
partners  
 1-5 87 (76.3) 84 (73.7) 0.646 127 (73.8) 0.636 
 More
than 5




85 (74.6) 76 (66.7) 0.191 138 (80.2) 0.257 
Consistent 
condom use (%) 
33 (38.8) 35 (46.1) 0.833 47 (34.3) 0.212 
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On ART (at final 
visit) 
91 (79.8) 12 (10.53) <0.0001 63 (36.6) <0.0001 
LTFU was defined as those who had their last visit date more than 1.5 years from 
the last date in the study and were not recorded as dead. 
*P values are for comparisons of Died to Retained 
**P values are for comparisons of LTFU to Retained 





Figure 3 shows the Kaplan Meier plot for SIL-free survival, stratified by ART status.  
Women with a baseline diagnosis of normal were included in the analysis.  This 
included 177 out of the 400 women.  Women were censored from the analysis upon 
receiving treatment for cervical disease.  The total person time at risk was 352 
person years.  The incidence rate of SIL in women not on ART was 28.5 per 100 
person years and in women who had initiated ART it was 30.82 per 100 person 
years.  The rate ratio was therefore 1.08 (95% CI 0.64-1.75). 
For women with a baseline viral load greater than log 5, there was a 25% increase 
in the incidence of SIL compared to women with a baseline viral load below log 5 
(rate ratio 1.25 95% CI 0.78-1.96).  Women who had baseline CD4 counts greater 
than 500 cells/mm3 at baseline had a 67% reduction against the incidence of SIL 
and those with CD4 counts of 201-500 cells/mm3 had a 37% reduction in the 
incidence of SIL compared to women with CD4 counts of 200 cells/mm3 and below 
(rate ratio 0.36 95% CI 0.18-0.68; 0.63 95% CI 0.40-0.99; respectively).  Baseline 
HPV positivity was the strongest predictor of progression to SIL.  Women who were 
positive for high risk HPV at baseline had an incidence rate of SIL 2.46 times higher 
than women who were HPV negative at baseline (95% CI 1.63-3.74).  There was no 
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Figure 3: Kaplan-Meier analysis of SIL-free survival in women on or not on ART. 
p=0.132 
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aged 29 years and younger (rate ratio 1.05 95% CI 0.67-1.64).  However women 
who were aged 40 years and older had a 58% reduction in the incidence of SIL 
compared to the youngest age group (rate ratio 0.42 95% CI 0.16-0.91). 
Table 4 shows the Cox proportional hazards models for incidence of SIL.  Overall, 
the crude hazard ratio for incidence of SIL for those on ART compared to those not 
on ART was 1.3 (95% CI 0.5-3.2).  After adjusting for CD4 count and age, the 
hazard ratio was 0.9 (95% CI 0.4-2.5), showing no difference in incidence of SIL 
between those on ART and those not on ART.  The crude hazard ratios showed that 
having a CD4 count above 200 cells/mm3 and being 40 years and older were 
protective against incidence of SIL (HR 0.5 95% CI 0.3-0.9; HR 0.5 95% CI 0.2-1.1; 
respectively).  Adjusted for ART, CD4 count and age, a higher CD4 count and older 
age were still protective. 
Disease progression to a diagnosis of SIL was also determined from the time of 
treatment of cervical disease.  The incidence rate of SIL following treatment was 
28.5 per 100 person years.  For those women on ART and not on ART, the 
incidence rate was 24.7 and 33.6 per 100 person years, respectively.  The incidence 
















































































































































































































































































































































































































































 Page 14 
 
Discussion 
Cervical cancer remains one of the commonest forms of cancer in women in 
developing countries, including South Africa.  The crude incidence and age-
standardised mortality rates for cervical cancer are 30.2 and 18 per 100 000, 
respectively2.  Cervical disease is progressive and develops over many years, 
involving the development of squamous intraepithelial lesions which can be detected 
by Pap smears and for which treatment is available.  In HIV positive women, this 
progression of cervical disease occurs more rapidly15,16.  This study examined the 
incidence of SIL development in HIV positive women and determined the incidence 
rate ratio between women on ART and women not on ART.  
Women were followed up for 9 years.  Follow up was censored at the first of either 
SIL diagnosis or treatment for cervical disease by LLETZ (large loop excision of the 
transformation zone).  Our primary finding was that there was no difference in the 
risk for SIL development between women receiving ART and women not receiving 
ART.  The incidence rate in women on ART was 28.5 per 100 person years 
compared to an incidence rate of 30.82 per 100 person years in women not on ART.  
The rate ratio in our cohort is therefore 1.08 (95% CI 0.64-1.75).   
Several studies have found conflicting results with respect to the effect of ART on 
cervical disease progression.  A study conducted in Soweto, South Africa found that 
ART was protective against SIL development (HR 0.72; 95% CI 0.52-0.99)17.  
However, this study reported cervical diagnoses based on cervical smears (i.e. 
cytological results) whereas we report histologic results.  However, one of their 
findings was that older age was protective against disease progression compared to 
the lowest age category (18-25 years), and in fact they found that older age was 
associated with regression of cervical disease.  This is in agreement with our finding 
of a 58% decrease in cervical disease progression in women older than 40 
compared to women younger than 40. 
Similarly, a cross-sectional study found that there was no statistical relationship 
between ART use and cervical disease18.  However, because the study was a cross-
sectional study it is only possible to comment on prevalence and not incidence of 
cervical disease progression. 
Heard et al19 found that the prevalence of SIL among HIV positive women 
decreased significantly after a median period of 5 months after starting ART.  A 
cohort study by Minkoff et al20 found that women on ART were 32% less likely to 
have progression of cervical disease over 6 months.  Soncini21 et al found that over 
a 37 month follow up period, women on ART had a 70% reduction in the risk for 
developing CIN compared to HIV positive women not on ART, over the same time 
period.  On the other hand, monitoring of the rate of progression of cervical disease 
in 163 HIV positive women over a mean period of 15.4 months13  showed that there 
was no difference between women on ART and women not on ART.  In addition, 
Schuman et al22 reported that ART-use did not result in a decreased risk of incident 
SIL. 
Approximately one third of the colposcopy diagnoses also had a histopathology 
result.  From these two, a composite diagnosis was derived and this was used in all 
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analyses.  Where histopathology was not available, the visual colposcopy diagnosis 
was used.  As far as we know this is the only cohort study which uses a composite 
diagnosis (where it is available) in analysis.  This is a much more reliable reading as 
visual inspection of the cervix by colposcopy is sensitive to the subjectivity of the 
interpreter.   
Sahasrabudde et al used a composite diagnosis in a cross-sectional study23 and 
found an increase in the odds of HSIL (CIN2 and CIN3) for women who were 
currently receiving ART compared to those who had never received ART (OR=2.24; 
95% CU 1.17-4.26).   
We found that immunological status was a predictor of SIL development, specifically 
that a baseline CD4 count greater than 500 cells/mm3 resulted in a 67% lowered 
likelihood of progression from a baseline cytological diagnosis of normal to a 
diagnosis of SIL, compared to a reference group whose baseline CD4 counts were 
200 cells/mm3 or less.  Similarly those with baseline CD4 counts between 201 and 
500 cells/mm3 had a 35% reduction in progression to SIL, compared to the 
reference group.  This is in agreement with findings of 2 other cohort24, 25 studies 
that used survival analysis to show that baseline CD4 counts greater than 200 
cells/mm3 were protective against SIL development.   
Thus far the study of the effect of ART on cervical disease progression in HIV 
positive women has been controversial.  Several different studies have yielded 
results that ranged from a decrease in the development of SIL to no difference in the 
outcomes between those on ART compared to those not on ART.  Our study has 
shown no difference in the hazard of SIL development between ART use and ART 
non-use.  A possible reason for the different results obtained could be the study 
inclusion criteria.  Soncini et al26 excluded women with a previous history of cervical 
intraepithelial neoplasia, and they found a 70% reduction in cervical disease in those 
on ART compared to those not on ART.  In our study, history of neoplasia was not 
an exclusion criterion.  This difference could result in an underestimation of the 
measure of effect in our study as women in the study may already have lesions that 
are somewhere along the continuum of cervical disease progression.  This is 
consistent with the theory on the genetic alteration of the cells within a lesion.  Once 
the cell has altered genetically, it cannot revert to its previous state of normality. 
ART is initiated based on immunological status.  However, immune reconstitution 
based on the use of ART cannot cause the cell to go back to its normal state and 
thus it will continue to progress pathologically27. 
In our study the women served as their own controls, in that the time a participant 
spent in the study before initiating ART was included in the analysis time of ART 
non-use.  This decreases the variance in the measurements taken in the study.  A 
limitation of the study is that we did not have an HIV negative group whose disease 
progression could have been compared to those participants with CD4 counts above 
500 cells/mm3. 
The loss to follow up in our study was high.  By the end of the 9-year period, 90% of 
the study participants were lost to follow up.  Nearly one third (29.3%) of the women 
died during the course of the study.  At the time, ART eligibility required a CD4 count 
of 200 cells/ml.  Thus, these women were more ill than if they were to be initiated at 
current ART initiation guidelines.  This may have resulted in the high rate of death. 
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The high numbers lost to follow up and to death could have resulted in an 
underestimation of the measure of effect, as a greater number of study participants 
for a longer period of time may be correlated with an increase in the observations of 
incident SILs. 
ART use is being scaled up in South Africa and therefore the lives of HIV positive 
women will be prolonged.  We found no difference in the risk of SIL development in 
HIV positive women who are on ART and those who have not yet initiated ART.  In 
light of this it is important that cervical screening and referral systems for colposcopy 
are strengthened to meet an important need. 
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